

Drugs for Immunotherapy Market Players Collaborate To Gain A Competitive Advantage

The Business Research Company's Drugs for Immunotherapy Global Market Report 2022 – Market Size, Trends, And Global Forecast 2022-2026

LONDON, GREATER LONDON, UK,
March 8, 2022 /EINPresswire.com/ --

[Drugs for immunotherapy market trends](#) include manufacturers

increasingly collaborating or partnering with other companies to share technology, resources, product knowledge and expand business. For


example, Illumina Inc. and Bristol-Myers Squibb (BMS) collaborated to utilize Illumina's next-generation sequencing (NGS) technology to develop and commercialize in-vitro diagnostic (IVD) assays in support of Bristol-Myers Squibb's oncology portfolio. Allogene Therapeutics Inc. and Pfizer Inc. entered into an asset contribution agreement to use Pfizer's portfolio of assets related to allogeneic CAR-T therapy.

Major players covered in the global drugs for immunotherapy industry are F. Hoffmann-La Roche Ltd, Novartis AG, Amgen, Inc., AbbVie, Inc., and Merck & Co. Inc., GlaxoSmithKline, Eli Lilly and Company, Bristol-Myers Squibb, AstraZeneca plc, Johnson & Johnson and UbiVac.

Read more on the Global Drugs for Immunotherapy Market Report:

<https://www.thebusinessresearchcompany.com/report/drugs-for-immunotherapy-global-market-report>

The global drugs for immunotherapy market size is expected to grow from \$186.39 billion in 2021 to \$208.56 billion in 2022 at a compound annual growth rate (CAGR) of 11.9%. The growth in the market is mainly due to the companies resuming their operations and adapting to the new normal while recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The immunotherapy drugs market is expected to reach \$310.48 billion in 2026 at a CAGR of 10.5%.



The [drugs for immunotherapy market growth](#) is being driven by rising incidences of cancer globally. The major causes for most cancers include obesity, smoking, alcohol, improper eating habits. According to the American Cancer Society, in 2019, around 606,880 deaths were caused in USA due to prevalence of the cancer. The Cancer Research UK predicts that there will be 27.5 million new cases of cancer each year by 2040. According to the drugs for immunotherapy market forecast analysis, the rising incidences of cancer are expected to increase the demand for immunotherapy drugs driving market growth.

TBRC's global drugs for immunotherapy market report is segmented by type into monoclonal antibodies, interferons, interleukins, vaccines, checkpoint inhibitors, others, by therapy area into cancer, autoimmune and inflammatory diseases, infectious diseases, others, by end-user into hospitals and clinics, ambulatory surgical centers, others.

Drugs For Immunotherapy Global Market Report 2022 – By Type (Monoclonal Antibodies, Interferons, Interleukins, Vaccines, Checkpoint Inhibitors), By Therapy Area (Cancer, Autoimmune And Inflammatory Diseases, Infectious Diseases), By End User (Hospitals And Clinics, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2022-2026 is one of a series of new reports from The Business Research Company that provides a drugs for immunotherapy market overview, forecast drugs for immunotherapy market size and growth for the whole market, drugs for immunotherapy market segments, geographies, drugs for immunotherapy market trends, drugs for immunotherapy market drivers, restraints, leading competitors' revenues, profiles, and market shares.

Request for a Sample of the Global Drugs for Immunotherapy Market Report:

<https://www.thebusinessresearchcompany.com/sample.aspx?id=2559&type=smp>

Not what you were looking for? Here is a list of similar reports by The Business Research Company:

Colorectal Cancer Drugs Global Market Report 2021 - By Type (Vascular Endothelial Growth Factor (VEGF) Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors, Programmed Cell Death Protein 1/PD1 Ligand 1 (PD1/PDL1) Inhibitors, BRAF or MEK Inhibitors, Tyrosine Kinase (TKI) Inhibitors, Immunomodulators), By Distribution Channels (Hospitals Pharmacies, Retail Pharmacies), By Class (Immunotherapy, Chemotherapy), COVID-19 Impact And Recovery

<https://www.thebusinessresearchcompany.com/report/colorectal-cancer-drugs-global-market-report>

Monoclonal Antibodies (MAbs) Global Market Report 2022 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular), By End-User (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/monoclonal-antibodies-global-market-report>

Vaccines Global Market Report 2022 – By Type (Anti-Infective Vaccines, Autoimmunity, Others (Cancer And Others)), By Technology (Conjugate Vaccines, Inactivated and Subunit Vaccines, Live Attenuated Vaccines, Recombinant Vaccines, Toxoid Vaccines), By Route of Administration (Intramuscular (IM), Subcutaneous (SC), Oral, Others), By Valance (Monovalent, Multivalent), By Distribution Channel (Institutional Sale, Hospital Pharmacies, Retail Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026

<https://www.thebusinessresearchcompany.com/report/vaccines-global-market-report>

About [The Business Research Company?](#)

The Business Research Company is a market research and intelligence firm that excels in company, market, and consumer research. It has over 200 research professionals at its offices in India, the UK and the US, as well a network of trained researchers globally. It has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services and technology.

Read more about us at <https://www.thebusinessresearchcompany.com/about-the-business-research-company.aspx>

Call us now for personal assistance with your purchase:

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Check out our:

LinkedIn: <https://bit.ly/3b7850r>

Twitter: <https://bit.ly/3b1rmjS>

YouTube: https://www.youtube.com/channel/UC24_fl0rV8cR5DxICpgmyFQ

Blog: <http://blog.tbrc.info/>

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/564968192>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2022 IPD Group, Inc. All Right Reserved.